Ferric nitrilotriacetate

Cat. No.: HY-145157 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis.

For research use only. We do not sell to patients.

Ferric nitrilotriacetate Chemical Structure

CAS No. : 16448-54-7

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis^[1].
In Vivo	Penitrem A can be used in animal modeling to construct models of tremor^[1]^[2]. 1. Induction of renal tumors^[3] Background Ferric nitrilotriacetate can induce oxidative stress, leading to lipid peroxidation of renal cell membranes and DNA damage, thereby promoting the development of renal tumors^[1]^[2]. Specific Mmodeling Methods Mice: A/J • male • 4-week-old Administration: 1.8-2.7 mg of Fe/kg • ip • once daily, 6 days a week for 12 weeks Note 1.8 to 2.7 mg refers to the amount of Fe contained in ferric nitrilotriacetate. Modeling Indicators Pathological Changes: The renal proximal tubular (PCT) cells in mice exhibit degeneration, necrosis, and shedding. Many PCT cells show regenerative characteristics, with some regenerative cells being abnormally large and featuring prominent nucleoli and mitoses. Some regenerative cells lack tubular formation. Phenotypic Observations: Renal tubular cell tumors develop. The appearance of renal tumors includes solid, cystic, or hemorrhagic forms. Microscopic examination reveals tumor cells with clear, granular, or spindle shapes, forming solid aggregates, papillae, cysts, or glandular patterns. Correlated Product(s): / Opposite Product(s): / 2. Induction of diabetes^[4] Background Ferric nitrilotriacetate causes significant iron deposition in the pancreas, leading to oxidative stress through the generation of reactive oxygen species (ROS) and free radicals. This results in damage and functional failure of pancreatic islet β-cells, reducing insulin secretion and consequently inducing diabetes.^[4]. Specific Mmodeling Methods Rat: Wistar • male and female Administration: 200 mg/rat • ip • once daily, Specifics of the administration method are detailed in the note Note MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	243.96
Formula	C₆H₆FeNO₆
CAS No.	16448-54-7
Appearance	Solid
Color	Light yellow to yellow
SMILES	O=C1[O-][Fe+3]([O-]C2=O)([O-]3)[N](C2)(C1)CC3=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Purity & Documentation	Purity: ≥98.0% Select Batch: Data Sheet (274 KB) SDS (252 KB) COA (246 KB) Handling Instructions (2659 KB)
References	[1]. Joël Essogo J, et al. Zanthoxylum heitzii Modulates Ferric Nitrilotriacetate-Dependent Oxidative Alterations in Four Vital Organs: An In Vitro Organoprotective Model. Evid Based Complement Alternat Med. 2017;2017:6058150. [Content Brief] [2]. Inoue S, et al. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987 Dec 15;47(24 Pt 1):6522-7. [Content Brief] [3]. Li JL, et al. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 1987 Apr 1;47(7):1867-9. [Content Brief] [4]. Awai M, et al. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol. 1979 Jun;95(3):663-73. PMID: 377994; [Content Brief]